MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection

[1]  G. Wang,et al.  Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern , 2022, NPJ vaccines.

[2]  G. Wang,et al.  mRNA vaccines elicit potent neutralization against multiple SARS-CoV-2 omicron subvariants and other variants of concern , 2022, iScience.

[3]  S. El-Kafrawy,et al.  The Qatar FIFA World Cup 2022 and camel pageant championships increase risk of MERS-CoV transmission and global spread. , 2022, The Lancet. Global health.

[4]  Diane J Post,et al.  Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant , 2022, Cell Reports Medicine.

[5]  S. Perlman,et al.  RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge , 2022, Translational Research.

[6]  Jianzhu Chen,et al.  Current Developments and Challenges of mRNA Vaccines. , 2022, Annual review of biomedical engineering.

[7]  Mark M. Davis,et al.  Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses , 2022, Science Translational Medicine.

[8]  Fang Li,et al.  Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. , 2022, Nanoscale.

[9]  Jiang Zhu,et al.  Advances in mRNA and other vaccines against MERS-CoV , 2021, Translational Research.

[10]  Monzurul A. Roni,et al.  Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines , 2021, Vaccines.

[11]  J. Granados-Riverón,et al.  Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2 , 2021, Biomedicine & Pharmacotherapy.

[12]  anonymous.  mRNA vaccines , 2021, Nature Biotechnology.

[13]  J. Meier,et al.  Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines , 2021, ACS central science.

[14]  Yvette N. Lamb.  BNT162b2 mRNA COVID-19 Vaccine: First Approval , 2021, Drugs.

[15]  L. Du,et al.  An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies , 2020, Expert review of vaccines.

[16]  C. Hillyer,et al.  A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2 , 2020, Cell Research.

[17]  Kai Zhao,et al.  Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[18]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[19]  Fang Li,et al.  MERS Coronavirus: An Emerging Zoonotic Virus , 2019, Viruses.

[20]  Z. Memish,et al.  Middle East respiratory syndrome coronavirus in the last two years: Health care workers still at risk , 2019, American Journal of Infection Control.

[21]  M. V. Van Kerkhove,et al.  MERS-CoV infection among healthcare workers and risk factors for death: Retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018 , 2019, Journal of Infection and Public Health.

[22]  L. Du,et al.  Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain , 2019, Viruses.

[23]  Jingwei Huang,et al.  Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain , 2019, Viruses.

[24]  Yufei Wang,et al.  A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV , 2018, Journal of Virology.

[25]  Kevin S. Naceanceno,et al.  Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen , 2018, Vaccine.

[26]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[27]  G. Gaus,et al.  Searching for the Ideal , 2017 .

[28]  Lu Lu,et al.  MERS-CoV spike protein: a key target for antivirals , 2017, Expert opinion on therapeutic targets.

[29]  S. Perlman,et al.  Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines , 2016, Nature Communications.

[30]  Yufei Wang,et al.  Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants , 2016, Journal of Virology.

[31]  Yufei Wang,et al.  A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection , 2016, Virology.

[32]  Shibo Jiang,et al.  Vaccines for the prevention against the threat of MERS-CoV , 2016, Expert review of vaccines.

[33]  Shibo Jiang,et al.  Middle East respiratory syndrome: current status and future prospects for vaccine development , 2015, Expert opinion on biological therapy.

[34]  Lu Lu,et al.  Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection , 2015, The Journal of infectious diseases.

[35]  Lu Lu,et al.  Receptor-binding domain-based subunit vaccines against MERS-CoV , 2014, Virus Research.

[36]  Shibo Jiang,et al.  Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments—The importance of immunofocusing in subunit vaccine design , 2014, Vaccine.

[37]  Z. Memish,et al.  Transmission of MERS-coronavirus in household contacts. , 2014, The New England journal of medicine.

[38]  R. Baric,et al.  Rapid generation of a mouse model for Middle East respiratory syndrome , 2014, Proceedings of the National Academy of Sciences.

[39]  Marion P G Koopmans,et al.  Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation , 2013, The Lancet Infectious Diseases.

[40]  R. Baric,et al.  Crystal Structure of the Receptor-Binding Domain from Newly Emerged Middle East Respiratory Syndrome Coronavirus , 2013, Journal of Virology.

[41]  Yi Shi,et al.  Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26 , 2013, Nature.

[42]  Christian Drosten,et al.  Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC , 2013, Nature.

[43]  A. Osterhaus,et al.  Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. , 2012, The New England journal of medicine.

[44]  Shibo Jiang,et al.  The spike protein of SARS-CoV — a target for vaccine and therapeutic development , 2009, Nature Reviews Microbiology.

[45]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.